Literature DB >> 21452023

bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer.

Pascal Jézéquel1, Mario Campone, Wilfried Gouraud, Catherine Guérin-Charbonnel, Christophe Leux, Gabriel Ricolleau, Loïc Campion.   

Abstract

Gene prognostic meta-analyses should benefit from breast tumour genomic data obtained during the last decade. The aim was to develop a user-friendly, web-based application, based on DNA microarrays results, called "breast cancer Gene-Expression Miner" (bc-GenExMiner) to improve gene prognostic analysis performance by using the same bioinformatics process. bc-GenExMiner was developed as a web-based tool including a MySQL relational database. Survival analyses are performed with R statistical software and packages. Molecular subtyping was performed by means of three single sample predictors (SSPs) and three subtype clustering models (SCMs). Twenty-one public data sets have been included. Among the 3,414 recovered breast cancer patients, 1,209 experienced a pejorative event. Molecular subtyping by means of three SSPs and three SCMs was performed for 3,063 patients. Furthermore, three robust lists of stable subtyped patients were built to maximize reliability of molecular assignment. Gene prognostic analyses are done by means of univariate Cox proportional hazards model and may be conducted on cohorts split by nodal (N), oestrogen receptor (ER), or molecular subtype status. To evaluate independent prognostic impact of genes relative to Nottingham Prognostic Index and Adjuvant! Online, adjusted Cox proportional hazards models are performed. bc-GenExMiner allows researchers without specific computation skills to easily and quickly evaluate the in vivo prognostic role of genes in breast cancer by means of Cox proportional hazards model on large pooled cohorts, which may be split according to different prognostic parameters: N, ER, and molecular subtype. Prognostic analyses by molecular subtype may also be performed in three robust molecular subtype classifications.

Entities:  

Mesh:

Year:  2011        PMID: 21452023     DOI: 10.1007/s10549-011-1457-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  153 in total

1.  The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes.

Authors:  Maryam Althobiti; Abir A Muftah; Mohammed A Aleskandarany; Chitra Joseph; Michael S Toss; Andrew Green; Emad Rakha
Journal:  Breast Cancer Res Treat       Date:  2020-06-10       Impact factor: 4.872

2.  The RasGAP gene, RASAL2, is a tumor and metastasis suppressor.

Authors:  Sara Koenig McLaughlin; Sarah Naomi Olsen; Benjamin Dake; Thomas De Raedt; Elgene Lim; Roderick Terry Bronson; Rameen Beroukhim; Kornelia Polyak; Myles Brown; Charlotte Kuperwasser; Karen Cichowski
Journal:  Cancer Cell       Date:  2013-09-09       Impact factor: 31.743

3.  CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.

Authors:  Hee-Joo Choi; Sora Jin; Hani Cho; Hee-Young Won; Hee Woon An; Ga-Young Jeong; Young-Un Park; Hyung-Yong Kim; Mi Kyung Park; Taekwon Son; Kyueng-Whan Min; Ki-Seok Jang; Young-Ha Oh; Jeong-Yeon Lee; Gu Kong
Journal:  EMBO Rep       Date:  2019-08-30       Impact factor: 8.807

Review 4.  Reuse of public genome-wide gene expression data.

Authors:  Johan Rung; Alvis Brazma
Journal:  Nat Rev Genet       Date:  2012-12-27       Impact factor: 53.242

5.  Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients.

Authors:  Christoforos Haritos; Kleita Michaelidou; Konstantinos Mavridis; Ioannis Missitzis; Alexandros Ardavanis; John Griniatsos; Andreas Scorilas
Journal:  Clin Exp Med       Date:  2018-02-12       Impact factor: 3.984

6.  Stromal integrin α11 regulates PDGFR-β signaling and promotes breast cancer progression.

Authors:  Irina Primac; Erik Maquoi; Silvia Blacher; Ritva Heljasvaara; Jan Van Deun; Hilde Yh Smeland; Annalisa Canale; Thomas Louis; Linda Stuhr; Nor Eddine Sounni; Didier Cataldo; Taina Pihlajaniemi; Christel Pequeux; Olivier De Wever; Donald Gullberg; Agnès Noel
Journal:  J Clin Invest       Date:  2019-07-09       Impact factor: 14.808

7.  A novel prognostic two-gene signature for triple negative breast cancer.

Authors:  Mansour A Alsaleem; Graham Ball; Michael S Toss; Sara Raafat; Mohammed Aleskandarany; Chitra Joseph; Angela Ogden; Shristi Bhattarai; Padmashree C G Rida; Francesca Khani; Melissa Davis; Olivier Elemento; Ritu Aneja; Ian O Ellis; Andrew Green; Nigel P Mongan; Emad Rakha
Journal:  Mod Pathol       Date:  2020-05-13       Impact factor: 7.842

8.  The transcriptional repressor BCL11A promotes breast cancer metastasis.

Authors:  Darcie D Seachrist; Molly M Hannigan; Natasha N Ingles; Bryan M Webb; Kristen L Weber-Bonk; Peng Yu; Gurkan Bebek; Salendra Singh; Steven T Sizemore; Vinay Varadan; Donny D Licatalosi; Ruth A Keri
Journal:  J Biol Chem       Date:  2020-06-23       Impact factor: 5.157

9.  Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis.

Authors:  Jianchao Zhang; Xinxin Lin; Liufeng Wu; Jia-Jia Huang; Wen-Qi Jiang; Thomas J Kipps; Suping Zhang
Journal:  Oncogene       Date:  2020-01-29       Impact factor: 9.867

10.  Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.

Authors:  Sarmad Al-Marsoummi; Emilie Vomhof-DeKrey; Marc D Basson
Journal:  Cell Physiol Biochem       Date:  2019
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.